Medical and ventilatory treatment of acute heart failure: New insights

Cardiology

Volumn 106, Issue 1, 2006, Pages 1-9

  Hodt, Anders ^a   Steine, Kjetil ^a   Atar, Dan ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Epidemiology; Heart failure; Ventilatory treatment

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; MORPHINE; NESIRITIDE; NITRIC ACID DERIVATIVE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; TEZOSENTAN;

ACUTE HEART FAILURE; ARTIFICIAL VENTILATION; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DRUG MEGADOSE; DYSPNEA; HUMAN; LUNG CONGESTION; LUNG EDEMA; LUNG VENTILATION; OXYGEN THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; CARDIOTONIC AGENTS; COMBINED MODALITY THERAPY; HEART FAILURE, CONGESTIVE; HUMANS; OXYGEN INHALATION THERAPY; RESPIRATION, ARTIFICIAL; VASODILATOR AGENTS;

EID: 33745713969     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092410     Document Type: Review

References (38)

1. Stewart S, MacIntyre K, Capewell S, McMurray JJV: Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003;89:49-53.
2. Jaagosild P, Dawson NV, Thomas C, Wenger NS, Tsevat J, Knaus WA, Califf RM, Goldman L, Vidaillet H, Connors AF Jr: Outcomes of acute exacerbation of severe congestive heart failure. Arch Intern Med 1998;158:1081-1089.
3. Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A: RITZ-5: randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. J Am Coll Cardiol 2003;41:204-210.
4. Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS: The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure. J Am Coll Card 2000;36(3 suppl A):1071-1076.
5. Nieminen MS, Bohm M, Cowie MR, et al,; ESC Committee for Practice Guideline (CPG): Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
6. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, Krakover R, Vered Z: The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003;5:443-451.
7. Mehta S: Continuous versus bilevel positive airway pressure in acute cardiogenic pulmonary edema? A good question! Crit Care Med 2004;32:2546-2548.
8. Mehta S, Jay GD, Woolard RH: Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med 1997;25:620-628.
9. Park M, Sangean MC, Volpe M, Feltrim M, Nozawa E, Leite P, Passos Amato M, Lorenzi-Filho G: Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med 2004;32:2407-2415.
10. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ: Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973;288:1087-1090.
11. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
12. Adams J, Mathur VS, Gheorghiade M: B-Type natriuretic peptide: from bench to bedside. Am Heart J 2003;145:S34-S46.
13. Rezakovic D, Rutishauser W, Pavicic L, Popadic M, Bloch A, Imhoff EW: Different hemodynamic actions of trinitroglycerin and isosorbide dinitrate in patients with acute myocardial infarction. Eur Heart J 1983;4:718-723.
14. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC Jr: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67:719-724.
15. Cernacek P, Stewart DJ: Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989;161:562-567.
16. Torre-Amione G, Young J, Colucci W, Lewis B, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink J, Frey A: Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-147.
17. McMurray J, Teerlink JR: Value of endothelin receptor inhibition with tezosentan in acute heart failure studies (Vertias). Annu Meet Am Coll Cardiol, Late Breaking Trials Plenary Session, 2005.
18. Adams J, Mathur VS, Gheorghiade M: B-type natriuretic peptide: from bench to bedside. Am Heart J 2003;145:S34-S46.
19. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW: Systemic hemodynamic, neurohormonal and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
20. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, Heitjan DF, Katz SD: Myocardial disease: hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1996;94:3184-3189.
21. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C, Chatterjee K: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. J Am Coll Cardiol 1999;34:155-162.
22. Colucci WS, Elkayam U, Horton D, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-253.
23. Young JB, Abraham WT, Stevenson LW, et al: Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002;287:1531-1540.
24. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A: Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-393.
25. Schwarz Pharma AG: Core Summary of Product Characteristics: Isoket i.v. vs. GTN i.v. Final Version, 4th rev, 1999, pp 1-17.
26. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C: Tolvaptan investigators: vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 2003;107:2690-2696.
27. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA: Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-2423.
28. Leier CV, Binkley PF: Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 1998;41:207-224.
29. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547.
30. O'Connor CM, Gattis W, Uretsky B, Adams KF, McNulty S, Grossman S, McKenna W, Zannad F, Swedberg K, Gheorghiade M, Califf R: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure. Am Heart J 1999;138:78-86.
31. Thackray S, Easthaugh J, Freemantle N, Cleland JGF: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. Eur J Heart Fail 2002;4:515-529.
32. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I: Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001;276:9337-9343.
33. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H: Influence of the novel motropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-2147.
34. + channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-259.
35. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-2227.
36. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study). Lancet 2002;360:196-202.
37. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J 2002;23:1422-1432.
38. Coletta AP, Cleland JGF, Freemantle N, Clark AL: Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail 2004;6:673-676.